Skip to main content

Table 2 Patient’s characteristics

From: Protective effect of early low-dose hydrocortisone on ventilator-associated pneumonia in the cancer patients: a propensity score analysis

Variables

Patients without VAP (n = 135)

Patients with VAP (n = 55)

P

Male gender, n (%)

87 (64.4)

41 (74.5)

0.23

Age (year), median (IQR)

59.2 (52.2–65.8)

60.4 (50.2–67.1)

0.99

Cancer type

  

0.39

 Haematological malignancy, n (%)

95 (70.4)

35 (63.6)

 

 Solid tumour, n (%)

40 (29.6)

20 (36.4)

 

Cancer stage

  

0.91

 Diagnosis, n (%)

36 (26.7)

15 (27.3)

 

 Complete remission, n (%)

29 (21.5)

13 (23.6)

 

 Partial remission, n (%)

31 (23)

14 (25.5)

 

 Evolutive, n (%)

39 (28.9)

13 (23.6)

 

HSCT, n (%)

47 (24.7)

14 (25.4)

0.43

Admission purpose

  

0.32

 Septic shock, n (%)

59 (43.7)

21 (38.2)

 

 Acute respiratory failure, n (%)

51 (37.8)

27 (49.1)

 

 Coma, n (%)

14 (10.4)

2 (3.6)

 

 Others, n (%)

11 (8.1)

5 (9.1)

 

Clinical sepsis upon admission

  

0.042

 Respiratory, n (%)

79 (58.5)

31 (56.4)

 

 Non-respiratory, n (%)

31 (23)

6 (10.9)

 

 None, n (%)

25 (18.5)

18 (32.7)

 

Characteristics upon admission

   

 Neutropenia, n (%)

54 (40)

18 (32.7)

0.41

 Antibiotherapy, n (%)

104 (77)

43 (78.2)

1

 Corticosteroids (curative), n (%)

32 (23.7)

19 (34.5)

0.15

SOFA score (day of intubation), median (IQR)

11 (8–14)

11 (8–13)

0.28

Characteristics at the first 48 h of MV

   

 Vasopressors, n (%)

99 (73.3)

44 (80)

0.36

 Renal replacement therapy, n (%)

28 (20.7)

9 (16.4)

0.55

 Substitutive hydrocortisone, n (%)

96 (71.1)

26 (47.3)

0.003

 G-CSF, n (%)

20 (14.8)

9 (16.4)

0.82

 Enteral nutrition, n (%)

40 (29.6)

21 (38.2)

0.3

 Antibiotherapy

  

0.09

  Adapted, n (%)

41 (30.4)

11 (20)

 

  Empirical, n (%)

89 (65.9)

38 (69)

 

  None, n (%)

5 (3.7)

6 (10.7)

 
  1. HSCT haematopoietic stem cell transplantation, G-CSF granulocyte colony-stimulating factors, MV mechanical ventilation, IQR interquartile range